- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04114266
Registry for Patients Undergoing AUS Surgery for Female SUI Due to ISD (VENUS)
Prospective Registry for Patients Undergoing Artificial Urinary Sphincter (AUS) Surgery for Female Stress Urinary Incontinence (SUI) Due to Intrinsic Sphincter Deficiency (ISD)
Study Overview
Status
Conditions
Detailed Description
This will be a prospective non-controlled cohort study evaluating the outcomes of artificial urinary sphincter (AUS) implantation surgery (Robot-assisted, Laparoscopic, Open or other) in female patients. The data collection will be undertaken from multiple centres in Europe. The participation will be by open invitation from the Urologists from the European Society of Female & Functional Urology Section of the European Association of Urology (ESFFU) to all its members along with other surgeons undertaking these procedures. The aim is to recruit a total of 150 patients in 2 years whereafter patients will be followed until the end of Registry which is 5 years after inclusion of the first patient. There will be no restriction on the number of patients enrolled as long as they are consecutive. The aim is to have a long-term collection of the dataset from as many centres as possible.
An initial assessment for the robustness of the data collection and first clinical evaluation of the data collected will be performed after 1 year by a nominated steering committee. Thereafter, the evaluations will be performed after every year until end of Registry.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Joni Kats, MSc
- Phone Number: +31263890677
- Email: j.kats@uroweb.org
Study Contact Backup
- Name: Wim Wtjes, Dr.
- Phone Number: +31263890677
- Email: w.witjes@uroweb.org
Study Locations
-
-
-
Antwerp, Belgium
- Not yet recruiting
- Universitair Ziekenhuis Antwerpen
-
Principal Investigator:
- Stephan De Wachter, Prof. Dr.
-
Gent, Belgium
- Not yet recruiting
- Universitair Ziekenhuis Gent
-
Principal Investigator:
- François Hervé, MD. PhD
-
Leuven, Belgium, 3000
- Recruiting
- University Hospital Leuven
-
Principal Investigator:
- Frank Van der Aa, Prof. Dr.
-
-
-
-
-
Prague, Czechia
- Recruiting
- Thomayer Hospital
-
Principal Investigator:
- Roman Zachoval, doc. MUDr
-
-
-
-
-
Bordeaux, France
- Recruiting
- University Hospital Bordeaux
-
Principal Investigator:
- Grégoire Capon, Dr
-
Le Mans, France
- Not yet recruiting
- Pôle Santé Sud
-
Principal Investigator:
- Olivier Belas, Dr.
-
Lille, France
- Recruiting
- CHU de Lille
-
Principal Investigator:
- Xavier Biardeau, Dr.
-
Limoges, France
- Recruiting
- CHU de Limoges
-
Principal Investigator:
- Aurelien Descazeaud, Prof. Dr.
-
Lyon, France
- Recruiting
- Hopital Lyon Sud
-
Principal Investigator:
- Alain Ruffion, Dr.
-
Marseille, France
- Recruiting
- Hopital La Conception
-
Principal Investigator:
- Gilles Karsenty, Prof.
-
Meudon, France
- Not yet recruiting
- Pole de Sante du Plateau
-
Principal Investigator:
- Vincent Cardot, Dr.
-
Nantes, France
- Recruiting
- Clinique urologique CHU de NANTES
-
Principal Investigator:
- Marie Aimee Perrouin Verbe, Dr.
-
Nîmes, France
- Recruiting
- University Hospital of Nîmes
-
Principal Investigator:
- Laurent Wagner, Dr.
-
Paris, France
- Recruiting
- Hôpital de la Pitié-Salpêtrière
-
Principal Investigator:
- Emmanuel Chartier-Kastler, Prof.
-
Rennes, France, 35000
- Recruiting
- University of Rennes, Department of Urology
-
Principal Investigator:
- Benoit Peyronnet, Dr.
-
Rouen, France
- Not yet recruiting
- Hopital Charles Nicolle
-
Principal Investigator:
- Jean-Nicolas Cornu
-
Suresnes, France
- Not yet recruiting
- Hôpital FOCH
-
Principal Investigator:
- Adrien Vidart
-
Toulouse, France
- Not yet recruiting
- CHU Rangueil
-
Principal Investigator:
- Xavier Game
-
Vandœuvre-lès-Nancy, France
- Recruiting
- Chu Nancy
-
Principal Investigator:
- Pierre Lecoanet, Prof. Dr.
-
-
-
-
-
Detmold, Germany
- Recruiting
- Klinikum Lippe
-
Principal Investigator:
- Karl-Dietrich Sievert, Dr.
-
-
-
-
-
Maastricht, Netherlands
- Recruiting
- Maastricht UMC+
-
Principal Investigator:
- Gommert van Koeveringe
-
-
-
-
-
Madrid, Spain
- Recruiting
- Hospital de La Princesa
-
Principal Investigator:
- Luis López-Fando Lavalle, Dr.
-
Madrid, Spain
- Recruiting
- Hospital Ramón y Cajal.
-
Principal Investigator:
- Mercedes Ruiz Hernández, PhD
-
Santander, Spain
- Recruiting
- Marqués de Valdecilla University Hospital
-
Principal Investigator:
- Paola Calleja Hermosa
-
-
-
-
-
Cambridge, United Kingdom
- Recruiting
- Addenbrooks Hospital
-
Principal Investigator:
- Nikesh Thiruchelvam, Prof. Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient should be Female and aged over 18 years.
- The patient will undergo an initial AUS implantation surgery (Robot-assisted, Laparoscopic, Open or other) for treatment of stress urinary incontinence due to intrinsic sphincter deficiency.
- Participant is willing and able to give informed consent for participation in the Registry
- Patient is able to complete the questionnaires.
Exclusion Criteria:
- Participating center is unable to contribute consecutive patients.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure rate
Time Frame: Up to 5 years post surgery
|
Cure rate is defined as urinary continence with no pads used or use of 1 light security pad.The cure rate after 5 years of study follow up will be calculated together with its 95% Confidence Intervals, for the total patient group as well as for each of the AUS implantation surgery procedures (Robot-assisted, Laparoscopic, Open, or other).
|
Up to 5 years post surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time being incontinence-free
Time Frame: Up to 5 years post surgery
|
Time being incontinence-free which is defined as the interval being continent after surgery to the date of incontinence recurrence
|
Up to 5 years post surgery
|
ICIQ-Urinary Incontinence-Short Form Questionnaire (ICIQ-UI-SF)
Time Frame: At each of the evaluation points up to 5 years post surgery
|
The ICIQ-UI-SF is a questionnaire evaluating 4 question items (Frequency or urinary incontinence, Amount of leakage, Overall impact of urinary incontinence, Self-diagnostic item) .
The score can range from 0 to 25. Mean ICIQ-UI-SF scores will be calculated at the indicated time points and numbers /percentages of patients in the different surgery categories.
Also change in ICIQ-UI-SF score compared to baseline will be calculated.
|
At each of the evaluation points up to 5 years post surgery
|
ICIQ-Female Sexual Matters Associated with Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)
Time Frame: At each of the evaluation points up to 5 years post surgery
|
The ICIQ-FLUTSsex is a questionnaire evaluating 4 question items (Pain/discomfort because of dry vagina, Impact of urinary symptoms, Pain with sexual intercourse, Urine leakage with sexual intercourse).
The score can range from 0 to 54. Mean ICIQ-FLUTSsex scores will be calculated at the indicated time points and numbers /percentages of patients in the different surgery categories.
Also change in ICIQ-FLUTSsex compared to baseline will be calculated.
|
At each of the evaluation points up to 5 years post surgery
|
ICIQ- Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)
Time Frame: At each of the evaluation points up to 5 years post surgery
|
The ICIQ-LUTSqol is a questionnaire evaluating 20 question items on quality of life in urinary incontinent patients with particular reference to social effects. The score can range from 19-76 overall score with greater values indicating increased impact on quality of life. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient. Mean ICIQ-LUTSqol scores will be calculated at the indicated time points and numbers /percentages of patients in the different surgery categories. Also change in ICIQ-LUTSqol compared to baseline will be calculated. |
At each of the evaluation points up to 5 years post surgery
|
24-hour pad tests
Time Frame: At each of the evaluation points up to 5 years post surgery
|
The results of the 24-hour pad tests (number of pads, grammes of leakage weight) at each of the evaluation points during follow up.
The change of results of the 24-hour pad tests will also be compared with baseline over time.
|
At each of the evaluation points up to 5 years post surgery
|
Urodynamic parameter Volume at leakage
Time Frame: At baseline, week 12 after surgery
|
The change of the Volume at leakage (ml) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Detrusor overactivity
Time Frame: At baseline, week 12 after surgery
|
The change of Detrusor overactivity (yes/no) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Maximum detrusor pressure during pressure-flow study
Time Frame: At baseline, week 12 after surgery
|
The change of Maximum detrusor pressure during pressure-flow study (cm H20) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Detrusor pressure at Max flow during pressure-flow study
Time Frame: At baseline, week 12 after surgery
|
The change of Detrusor pressure at Max flow during pressure-flow study (cm H20) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Maximum urinary flow during pressure-flow study
Time Frame: At baseline, week 12 after surgery
|
The change of Maximum urinary flow during pressure-flow study (ml/s) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Maximum cystometric capacity
Time Frame: At baseline, week 12 after surgery
|
The change of Maximum cystometric capacity (ml) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Urodynamic parameter Retrograde leak point pressure
Time Frame: At baseline, week 12 after surgery
|
The change of Retrograde leak point pressure (cm H20) will be compared with baseline.
|
At baseline, week 12 after surgery
|
Main conclusion of Urodynamic investigations
Time Frame: At baseline, week 12 after surgery
|
Main conclusion of Urodynamic investigations (Pure stress incontinence, Pure urgency incontinence, Mixed stress, urgency incontinence) will be compared with baseline.mic
investigation (Pure stress incontinence, Pure urgency incontinence, Mixed stress, urgency incontinence).The change of Urodynamic parameters will be compared with baseline.
|
At baseline, week 12 after surgery
|
Maximum free urinary flow
Time Frame: At baseline, week 6, week 12 after surgery
|
The change in Maximum free urinary flow (ml/s) will be compared to baseline.
|
At baseline, week 6, week 12 after surgery
|
Post void Residual Volume
Time Frame: At baseline, week 6, week 12 after surgery
|
The change in Post void Residual Volume (ml) will be compared to baseline.
|
At baseline, week 6, week 12 after surgery
|
Number of patients with complications
Time Frame: During surgery and up to 5 years after surgery
|
Type of complications, associated symptoms and whether or not a revision was needed will be recorded.
|
During surgery and up to 5 years after surgery
|
Time being revision-free
Time Frame: Up to 5 years post-surgery
|
The interval from the date of surgery to the date of revision whereby revision is defined as any urogenital surgical intervention that is related to the function, placement, or site reaction to the implanted device
|
Up to 5 years post-surgery
|
Revision-free rate
Time Frame: At 1, 2, 3, 4, 5 years of Registry follow-up
|
The number of patients who are revision-free compared to the total number of patients, whereby revision is defined as any urogenital surgical intervention that is related to the function, placement, or site reaction to the implanted device
|
At 1, 2, 3, 4, 5 years of Registry follow-up
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Benoit Peyronnet, Dr., Rennes University Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Urological Manifestations
- Elimination Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Incontinence
- Lower Urinary Tract Symptoms
- Enuresis
- Urinary Incontinence, Stress
- Urologic Diseases
- Urination Disorders
Other Study ID Numbers
- EAU-RF 2019-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urologic Diseases
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
Chang Gung Memorial HospitalCompleted
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaboratorsRecruiting
-
Diskapi Yildirim Beyazit Education and Research...Unknown
-
Fundación Pública Andaluza para la gestión de la...RecruitingSurgery | Anesthesia | Urologic CancerSpain
-
IRCCS San RaffaeleRecruitingUrologic Diseases | Infertility | Urologic CancerItaly
-
Changhai HospitalUTC Therapeutics Inc.RecruitingCD70-positive Advanced Urologic NeoplasmsChina
-
Yonsei UniversityCompletedPediatric Urologic SurgeriesKorea, Republic of
-
Yonsei UniversityCompletedElective Urologic SurgeriesKorea, Republic of
-
Kasr El Aini HospitalUnknownUrologic Surgical ProceduresEgypt
Clinical Trials on Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)
-
Koç UniversityNot yet recruitingQuality of Life | Incontinence, Urge | Incontinence Stress